daratumumab,nivolumab,ipilimumab,relatlimab
janssen,bms
['cm358', 'nivo']
#merkelcellcarcinoma study at #asco23 2 cohort study showed combo of ipi-nivo no better than nivo. but! non-randomized design confounds interpretation a rare tumour and hard to conduct - still, we must conduct randomized trials to move field forward #cm358
Professor of Oncology @Otago, working in research, policy, implementation, and clinical practice. Health is political! Views = own. He/him.